u/Smooth_Ninja_1191

Novo has fallen sharply while obesity demand remains structurally underpenetrated; the market is focused on competition and near-term setbacks. If current bad news is mostly priced in, successful pipeline execution can restore growth and drive the stock toward the author’s 100 target. Long NVO at current levels as a contrarian value play on Novo’s long-term growth optionality in obesity and cardiometabolic disease. Intensifying competition, clinical or regulatory pipeline failures, and continued negative sentiment could invalidate the thesis.